ELAN
Price
$23.49
Change
-$0.06 (-0.25%)
Updated
Oct 19, 04:59 PM (EDT)
Capitalization
11.77B
18 days until earnings call
Intraday BUY SELL Signals
KMDA
Price
$7.63
Change
-$0.13 (-1.68%)
Updated
Oct 19, 04:59 PM (EDT)
Capitalization
447.83M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs KMDA

ELAN vs KMDA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ELAN vs. KMDA commentary
Oct 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and KMDA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ELAN with price predictions
Oct 16, 2026

ELAN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ELAN turned positive on October 05, 2026. Looking at past instances where ELAN's MACD turned positive, the stock continued to rise in 35 of 48 cases over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on ELAN as a result. In 50 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

ELAN moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAN advanced for three days, in 172 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 50-day moving average for ELAN moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

ELAN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ELAN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ELAN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.786) is normal, around the industry mean (10.234). P/E Ratio (-57.439) is within average values for comparable stocks, (-6.027). Projected Growth (PEG Ratio) (4.042) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (2.275) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for KMDA with price predictions
Oct 16, 2026

KMDA in downward trend: 10-day moving average broke below 50-day moving average on October 13, 2026

The 10-day moving average for KMDA crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMDA as a result. In 57 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.

The Moving Average Convergence Divergence Histogram (MACD) for KMDA turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 34 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

KMDA moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 68 cases where KMDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The 50-day moving average for KMDA moved above the 200-day moving average on September 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

KMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 95 of 160 cases where KMDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.661) is normal, around the industry mean (10.234). P/E Ratio (20.421) is within average values for comparable stocks, (-6.027). Projected Growth (PEG Ratio) (0.644) is also within normal values, averaging (2.152). Dividend Yield (0.088) settles around the average of (0.039) among similar stocks. P/S Ratio (2.487) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. KMDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
ELAN vs KMDA: Fundamental Ratings
ELAN
KMDA
OUTLOOK RATING
1..100
1250
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
6
Undervalued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
9276
PRICE GROWTH RATING
1..100
5148
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for ELAN (54) in the Agricultural Commodities Or Milling industry. This means that KMDA’s stock grew somewhat faster than ELAN’s over the last 12 months.

KMDA's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that KMDA’s stock grew somewhat faster than ELAN’s over the last 12 months.

KMDA's SMR Rating (76) in the Biotechnology industry is in the same range as ELAN (92) in the Agricultural Commodities Or Milling industry. This means that KMDA’s stock grew similarly to ELAN’s over the last 12 months.

KMDA's Price Growth Rating (48) in the Biotechnology industry is in the same range as ELAN (51) in the Agricultural Commodities Or Milling industry. This means that KMDA’s stock grew similarly to ELAN’s over the last 12 months.

KMDA's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that KMDA’s stock grew somewhat faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANKMDA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
68%
Momentum
ODDS (%)
Bullish Trend 4 days ago
61%
Bearish Trend 4 days ago
56%
MACD
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
65%
Advances
ODDS (%)
Bullish Trend 4 days ago
66%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 6 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
73%
Aroon
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
59%
COMPARISON
Comparison
Oct 19, 2026
Stock price -- (ELAN: $23.55 vs. KMDA: $7.76)
Brand notoriety: ELAN: Notable vs. KMDA: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 97% vs. KMDA: 25%
Market capitalization -- ELAN: $11.77B vs. KMDA: $447.83M
ELAN [@Pharmaceuticals: Generic] is valued at $11.77B. KMDA’s [@Pharmaceuticals: Generic] market capitalization is $447.83M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green while KMDA’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • KMDA’s FA Score: 1 green, 4 red.
According to our system of comparison, KMDA is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 4 TA indicator(s) are bullish while KMDA’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 4 bullish, 5 bearish.
  • KMDA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than KMDA.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +2.75% price change this week, while KMDA (@Pharmaceuticals: Generic) price change was -3.96% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.72%. For the same industry, the average monthly price growth was -7.71%, and the average quarterly price growth was +7.81%.

Reported Earning Dates

ELAN is expected to report earnings on Nov 06, 2026.

KMDA is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.72% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.